Which company does Selinexor come from?

Selinexor (Selinexor) was developed by Karyopharm Therapeutics, a pharmaceutical company focused on developing drugs that target nuclear transport. It was approved in the United States in July 2019, based on a single-arm Phase IIb clinical trial. The combination of selinesol and dexamethasone received accelerated approval and was designated as an orphan drug. The U.S. Food and Drug Administration (FDA) granted approval of selinesol to Karyopharm Therapeutics, under the trade name Xpovio and marketed in the EU under the trade name Nexpovio.

In June 2020, the FDA approved an additional indication for selinesol for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL caused by follicular lymphoma, after at least two systemic therapies. The most common side effects of selinesol include nausea, vomiting, decreased appetite, weight loss, diarrhea, fatigue, thrombocytopenia (low platelet count), anemia (low red blood cell count), low white blood cell levels, and hyponatremia (low blood sodium level).

The original drug Seleniso has been launched in China, but it has not yet entered the scope of medical insurance. Specifications The price of 20mg*12 tablets per box may be around 20,000 yuan. The US version of the original Seleniso drug sold overseas, with a specification of 20mg*8 tablets, may cost more than 100,000 yuan per box (the price may fluctuate due to exchange rates), which is very expensive. Currently, there are also generic Selinisol drugs produced and marketed overseas. The price of a box of 20mg*16 tablets produced by a Lao pharmaceutical factory may be around RMB 4,000 (the price may fluctuate due to the exchange rate). Its drug ingredients are basically the same as those of the original drugs sold domestically and abroad.